Pay in 4 interest-free payments of $5.15 Learn more
Ships within 48 hours · Estimated delivery Sep 24 - Sep 29
event-driven endpoint Obstructive Sleep Apnea Status: Phase 3 Planned Focus: OSA severity reduction (apnea-hypopnea index) with CagriSema-induced weight loss Population: Adults with moderate-severe OSA and obesity Timeline: Expected enrollment 2024-2025 NASH/MAFLD Status: Phase 2 Ongoing Focus: Hepatic steatosis, inflammation, and fibrosis improvement Population: Adults with biopsy-confirmed NASH/MAFLD Timeline: Results expected 2025 Heart Failure with Preserved EF Status: Preclinical Planning Focus: HFpEF outcomes in obese patients following substantial weight loss Rationale: Obesity-HFpEF phenotype may benefit from profound weight reduction Timeline: Early development phase Pediatric Obesity Status: Phase 2 Planning Focus: Safety, tolerability, and efficacy in adolescents (12-18 years) Population: Adolescents with obesity (BMI 95th percentile) Timeline: Expected initiation 2025 Oral Formulation Development Status: Preclinical Focus: Oral bioavailability enhancement for cagrilintide using absorption enhancers Rationale: Oral delivery could improve accessibility and adherence Timeline: Research phase
We are conveniently located at 850 Iron Point Rd Suite 114, Folsom, CA 95630
Transdermal drug delivery isn't new nicotine patches, hormone therapies, and nitrate medications have been crossing the skin barrier for decades
Serevent Diskus (salmeterol xinafoate inhalation powder) package insert
Ethics declarations Funding No sources of funding were used to assist in the preparation of this manuscript
Key Takeaways GLP-1 medications like semaglutide (Wegovy, Ozempic), tirzepatide (Zepbound, Mounjaro), and orforglipron (Foundayo) are available online through telehealth and licensed pharmacies
